Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MMP2 | P08253 | 2/20 | 0.36 |
| ▸ | MMP9 | P14780 | 2/20 | 0.36 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6535237 | 0.90 | SMN1; SMN2 (0.41) | TP53LMNAALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL8429588 | 0.86 | LMNA (0.39) | TP53LMNAALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL8429495 | 0.86 | LMNA (0.39) | TP53LMNAALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL7342248 | 0.84 | ALDH1A1 (0.40) | TP53LMNAALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL7342254 | 0.84 | ALDH1A1 (0.40) | TP53LMNAALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL28294340 | 0.84 | KMT2A (0.40) | TP53LMNAALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL7345170 | 0.83 | MMP2 (0.40) | TP53LMNAALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL6464595 | 0.83 | ALDH1A1 (0.39) | TP53LMNAALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL29033834 | 0.81 | ALDH1A1 (0.40) | TP53LMNAALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL6930707 | 0.80 | CTNNB1 (0.43) | LMNAALDH1A1SMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005053607-A2 | METHOD FOR PREVENTING HEPATIC ENCEPHALOPATHIC EPISODES | MEDICIS PHARMACEUTICAL CORPORATION (US) | 2005-06-16 | — | — | WO | claimed |
| US-20040229948-A1 | Method for preventing hepatic encephalopathic episodes | MEDICIS PHARMACEUTICAL CORPORATION | 2004-11-18 | — | — | US | claimed |
| US-20240041807-A1 | COMBINATION THERAPY TO TREAT UREA CYCLE DISORDERS | BAYLOR COLLEGE OF MEDICINE | 2024-02-08 | — | — | US | disclosed |
| US-11819483-B2 | Combination therapy to treat urea cycle disorders | BAYLOR COLLEGE OF MEDICINE (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230181504-A1 | COMBINATION THERAPY TO TREAT UREA CYCLE DISORDERS | BAYLOR COLLEGE OF MEDICINE | 2023-06-15 | — | — | US | disclosed |
| US-11517547-B2 | Combination therapy to treat urea cycle disorders | BAYLOR COLLEGE OF MEDICINE (US) | 2022-12-06 | — | — | US | disclosed |
| US-20200170984-A1 | COMBINATION THERAPY TO TREAT UREA CYCLE DISORDERS | BAYLOR COLLEGE OF MEDICINE | 2020-06-04 | — | — | US | disclosed |
| EP-3645053-A1 | COMBINATION THERAPY TO TREAT UREA CYCLE DISORDERS | Baylor College of Medicine (US) | 2020-05-06 | — | — | EP | disclosed |
| WO-2019006164-A1 | COMBINATION THERAPY TO TREAT UREA CYCLE DISORDERS | BAYLOR COLLEGE OF MEDICINE (US) | 2019-01-03 | — | — | WO | disclosed |
| US-9322893-B2 | Methods of distinguishing between glutamine formed by cataplerosis or proteolysis | BIOCANT-ASSOCIAÇÃO DE TRANSFERÊNCIA DE TECNOLOGIA (PT) | 2016-04-26 | — | — | US | disclosed |
| EP-2286238-B1 | METHODS OF DISTINGUISHING BETWEEN GLUTAMINE FORMED BY CATAPLEROSIS OR PROTEOLYSIS | BIOCANT ASSOCIACAO DE TRANSFERENCIA DE TECNOLOGIA (PT) | 2012-03-21 | — | — | EP | disclosed |
| US-20110079093-A1 | Methods of Distinguishing Between Glutamine Formed by Cataplerosis or Proteolysis | BIOCANT (PT) | 2011-04-07 | — | — | US | disclosed |
| EP-2286238-A1 | METHODS OF DISTINGUISHING BETWEEN GLUTAMINE FORMED BY CATAPLEROSIS OR PROTEOLYSIS | Biocant - Associação De Transferência De Tecnologia (PT) | 2011-02-23 | — | — | EP | disclosed |
| WO-2009141619-A1 | METHODS OF DISTINGUISHING BETWEEN GLUTAMINE FORMED BY CATAPLEROSIS OR PROTEOLYSIS | Biocant - Associação De Transferência De Tecnologia (PT) | 2009-11-26 | — | — | WO | disclosed |
| WO-2005053607-A2 | METHOD FOR PREVENTING HEPATIC ENCEPHALOPATHIC EPISODES | MEDICIS PHARMACEUTICAL CORPORATION (US) | 2005-06-16 | — | — | WO | disclosed |
| US-20040229948-A1 | Method for preventing hepatic encephalopathic episodes | MEDICIS PHARMACEUTICAL CORPORATION | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229948-A1 | Method for preventing hepatic encephalopathic episodes | OAT, PYGL, SLC10A1 | TP53 4406/4885LMNA 1753/4885ALDH1A1 1028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.